|
The following stocks are the leading risers and fallers on AIM on Wednesday. ---------- AIM - WINNERS ---------- System1 Group PLC, up 11% at 240 pence, 12-month range 216p-635p. The marketing firm reports revenue of £8.3 million for the quarter to September 30, down 6% year-on-year from £8.9 million, with platform revenue slipping 3% to £7.9 million from £8.1 million as continued to see ‘lower, but ongoing, spend’ from many of its largest clients, due to the ‘wider macroeconomic uncertainty’. Half-year revenue falls 7% to £17.1 million from £18.3 million. Gross margin remains strong at 87%, and cash rises to £10.8 million. Chief Executive James Gregory says trading is in line with guidance and that ‘October is looking strong’. ---------- Virgin Wines UK PLC, up 5.5% at 51.5p, 12-month range 30.5p-79p. The online wine retailer reports full-year revenue of £59.0 million, unchanged from the prior year, and pretax profit of £1.6 million versus £1.7 million. Virgin Wines says trading so far in the new financial year remains in line with market expectations and expresses confidence in achieving sustainable long-term growth. ---------- AIM - LOSERS ---------- Polarean Imaging PLC, down 44% at 0.225p, 12-month range 0.225p-1.65p. The medical imaging technology company says its board has launched a strategic review of the firm’s direction and structure amid a ‘highly challenging’ UK small-cap market for MedTech stocks. Polarean says it is assessing options to maximise shareholder value, including cost reductions and potentially cancelling its AIM listing to transition to a private company structure. The firm says no decision has been made and any delisting would require shareholder approval. Polarean adds it remains focused on advancing its Xenon MRI technology and commercial growth during the review. ---------- Oxford BioDynamics PLC, down 37% at 0.315p, 12-month range 0.255p-2.2p. The precision diagnostics company raises £7 million through a placing and subscription of 2.33 billion new shares at £0.003 each, representing around 54% of the enlarged share capital. The funds will provide working capital as sales of its EpiSwitch-based PSE prostate cancer test continue to rise and the firm pursues new out-licensing and distribution deals. A general meeting will be held on November 7 to approve the share issue. Executive Chair Iain Ross says: ‘Whilst our PSE Test sales continue to grow month on month, our new partnership with Google Cloud is progressing and third party partnership discussions are ongoing, these funds will help us to execute our plans to create increasing value for our shareholders.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
